Pharmacologic Stabilization and Management of Acute Heart Failure Syndromes in the Emergency Department

Gheorghiade, 2005, International working group on acute heart failure syndromes. Acute heart failure syndromes: current state and framework for future research, Circulation, 112, 3958, 10.1161/CIRCULATIONAHA.105.590091 Adams, 2005, Am Heart J, 149, 209, 10.1016/j.ahj.2004.08.005 Cleland, 2003, Eur Heart J, 24, 442, 10.1016/S0195-668X(02)00823-0 Heart Failure Society Of America, 2006, Executive summary: HFSA 2006 comprehensive heart failure practice guideline, J Card Fail, 12, 10, 10.1016/j.cardfail.2005.12.001 Nieminen, 2005, ESC committee for practice guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European society of cardiology, Eur Heart J, 26, 384, 10.1093/eurheartj/ehi044 De Luca, 2007, Early pharmacological treatment of acute heart failure syndromes: a systematic review of clinical trials, Acute Card Care, 9, 10, 10.1080/17482940601134487 Gheorghiade, 2005, Pathophysiologic targets in the early phase of acute heart failure syndromes, Am J Cardiol, 96, 11G, 10.1016/j.amjcard.2005.07.016 Sackner-Bernstein, 2005, Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure, Circulation, 111, 1487, 10.1161/01.CIR.0000159340.93220.E4 Sackner-Bernstein, 2005, Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials, JAMA, 293, 1900, 10.1001/jama.293.15.1900 Zannad, 2006, Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study, Eur J Heart Fail, 8, 697, 10.1016/j.ejheart.2006.01.001 Gheorghiade, 2006, Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure, JAMA, 296, 2217, 10.1001/jama.296.18.2217 Alla, 2007, Epidemiology of acute heart failure syndromes, Heart Fail Rev, 12, 91, 10.1007/s10741-007-9009-2 Chatti, 2007, Algorithm for therapeutic management of acute heart failure syndromes, Heart Fail Rev, 12, 113, 10.1007/s10741-007-9013-6 Weinfeld, 1999, Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure, Am Heart J, 138, 285, 10.1016/S0002-8703(99)70113-4 Cooper, 1999, Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction, Circulation, 100, 1311, 10.1161/01.CIR.100.12.1311 Jhund, 2000, The acute vascular effects of furosemide in heart failure, Br J Clin Pharmacol, 50, 9, 10.1046/j.1365-2125.2000.00219.x Gottlieb, 2002, BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy, Circulation, 105, 1348, 10.1161/hc1102.105264 Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 1997;62:187–93. Cotter, 1998, Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema, Lancet, 351, 389, 10.1016/S0140-6736(97)08417-1 Lahav, 1992, Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure, Chest, 102, 725, 10.1378/chest.102.3.725 Dormans, 1996, Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion, J Am Coll Cardiol, 28, 376, 10.1016/0735-1097(96)00161-1 Cohn, 1974, Physiologic and clinical actions of nitroglycerin, Med Clin North Am, 58, 407, 10.1016/S0025-7125(16)32167-8 Elkayam, 2004, Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations, J Cardiovasc Pharmacol Ther, 9, 227, 10.1177/107424840400900403 Katz, 1992, Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure, J Am Coll Cardiol, 19, 918, 10.1016/0735-1097(92)90271-N Elkayam, 1987, Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation, Am J Cardiol, 60, 1106, 10.1016/0002-9149(87)90362-6 Loh, 2001, A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure, J Card Fail, 7, 114, 10.1054/jcaf.2001.24136 Nashed, 1995, Intravenous nitroglycerin boluses in treating patients with cardiogenic pulmonary edema, Am J Emerg Med, 13, 612, 10.1016/0735-6757(95)90189-2 Levy, 2007, Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis, Ann Emerg Med, 50, 144, 10.1016/j.annemergmed.2007.02.022 2002, Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial, JAMA, 287, 1531, 10.1001/jama.287.12.1531 Levin, 1998, Natriuretic peptides, N Engl J Med, 339, 321, 10.1056/NEJM199807303390507 Mills, 1999, Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor study group, J Am Coll Cardiol, 34, 155, 10.1016/S0735-1097(99)00184-9 Colucci, 2000, Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide study group, N Engl J Med, 343, 246, 10.1056/NEJM200007273430403 Guiha, 1974, Treatment of refractory heart failure with infusion of nitroprusside, N Engl J Med, 291, 587, 10.1056/NEJM197409192911201 Khot, 2003, Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis, N Engl J Med, 348, 1756, 10.1056/NEJMoa022021 Cohn, 1982, Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study, N Engl J Med, 306, 1129, 10.1056/NEJM198205133061902 Bussmann, 1978, Effect of sublingual nitroglycerin in emergency treatment of severe pulmonary edema, Am J Cardiol, 41, 931, 10.1016/0002-9149(78)90736-1 Fonarow, 2004, ADHERE scientific advisory committee. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry, Heart Fail Rev, 9, 179, 10.1007/s10741-005-6127-6 Milo-Cotter, 2007, Acute heart failure associated with high admission blood pressure—a distinct vascular disorder?, Eur J Heart Fail, 9, 178, 10.1016/j.ejheart.2006.06.004 Thackray, 2002, The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis, Eur J Heart Fail, 4, 515, 10.1016/S1388-9842(02)00041-7 Packer, 1993, The search for the ideal positive inotropic agent, N Engl J Med, 329, 201, 10.1056/NEJM199307153290310 Papp, 2005, Pharmacological mechanisms contributing to the clinical efficacy of levosimendan, Cardiovasc Drug Rev, 23, 71, 10.1111/j.1527-3466.2005.tb00158.x Mebazaa, 2005, Randomized clinical trials with levosimendan, Am J Cardiol, 96, 74G, 10.1016/j.amjcard.2005.07.024 Cleland, 2006, Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE, Eur J Heart Fail, 8, 105, 10.1016/j.ejheart.2005.12.003 Mebazaa, 2007, SURVIVE investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial, JAMA, 297, 1883, 10.1001/jama.297.17.1883 Munger, 2006, Management of acute decompensated heart failure: treatment, controversy, and future directions, Pharmacotherapy, 26, 131S, 10.1592/phco.26.8part2.131S Zannad, 2006, The challenge of acute decompensated heart failure, Heart Fail Rev, 11, 135, 10.1007/s10741-006-9484-x Felker, 2001, Inotropic therapy for heart failure: an evidence-based approach, Am Heart J, 142, 393, 10.1067/mhj.2001.117606 Parissis, 2007, Classical inotropes and new cardiac enhancers, Heart Fail Rev, 12, 149, 10.1007/s10741-007-9014-5 O'Connor, 1999, Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST), Am Heart J, 138, 78, 10.1016/S0002-8703(99)70250-4 Follath, 2002, Steering committee and investigators of the levosimendan infusion versus dobutamine (LIDO) study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial, Lancet, 360, 196, 10.1016/S0140-6736(02)09455-2 Cuffe, 2002, Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial, JAMA, 287, 1541, 10.1001/jama.287.12.1541 Figgit, 2001, Levosimendan, Drugs, 61, 613, 10.2165/00003495-200161050-00006 Perrone, 2005, Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure, Int J Cardiol, 103, 248, 10.1016/j.ijcard.2004.12.012 Kivikko, 2005, Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure, Curr Pharm Des, 11, 435, 10.2174/1381612053382043 Parissis, 2005, Levosimendan for the treatment of acute heart failure syndromes, Expert Opin Pharmacother, 6, 2741, 10.1517/14656566.6.15.2741 DeLuca, 2006, Evidence-based use of levosimendan in different clinical settings, Eur Heart J, 27, 1908, 10.1093/eurheartj/ehi875 Moiseyev, 2002, Study investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN), Eur Heart J, 23, 1422, 10.1053/euhj.2001.3158 Packer M. The randomized multicenter evaluation of intravenous levosimendan efficacy-2 (REVIVE-2) trial. Late-breaking clinical trials. American Heart Association. Presented at the Annual Scientific Session, Dallas (TX), 13–16 November 2005. Peacock, 2008, Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis, Emerg Med J, 25, 205, 10.1136/emj.2007.050419 Swedberg, 1992, Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the cooperative new Scandinavian enalapril survival study II (CONSENSUS II), N Engl J Med, 327, 678, 10.1056/NEJM199209033271002 Annane, 1996, Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema, Circulation, 94, 1316, 10.1161/01.CIR.94.6.1316 Pitt, 1999, For the randomized Aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 Mebazaa, 2008, Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes, Crit Care Med, 36, S129, 10.1097/01.CCM.0000296274.51933.4C